Sugi Predict

Sugi Predict / Targets / PDE6B

PDE6B

Rod cGMP-specific 3',5'-cyclic phosphodiester · P35913 · PDE6B on Sugi Atlas →

12,145 patent compounds predicted against PDE6B, 9,903 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1327741 SCHEMBL1327741 0.79 6/20
SCHEMBL1327318 SCHEMBL1327318 0.81 5/20
SCHEMBL1327321 SCHEMBL1327321 0.81 5/20
SCHEMBL1327324 SCHEMBL1327324 0.81 5/20
SCHEMBL972494 SCHEMBL972494 0.72 5/20
SCHEMBL972096 SCHEMBL972096 0.60 5/20
SCHEMBL2792231 SCHEMBL2792231 0.54 5/20
SCHEMBL969605 SCHEMBL969605 0.77 4/20
SCHEMBL2791914 SCHEMBL2791914 0.63 4/20
SCHEMBL2485688 SCHEMBL2485688 0.58 4/20
SCHEMBL969760 SCHEMBL969760 0.51 4/20
SCHEMBL1696249 SCHEMBL1696249 0.51 4/20
SCHEMBL2576880 SCHEMBL2576880 1.00 3/20
SCHEMBL2568447 SCHEMBL2568447 0.74 3/20
SCHEMBL968670 SCHEMBL968670 0.73 3/20
SCHEMBL972290 SCHEMBL972290 0.73 3/20
SCHEMBL971800 SCHEMBL971800 0.72 3/20
SCHEMBL867299 SCHEMBL867299 0.72 3/20
SCHEMBL1326458 SCHEMBL1326458 0.72 3/20
SCHEMBL1922041 SCHEMBL1922041 0.72 3/20

Clinical trials — most relevant to PDE6B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i PHASE4UNKNOWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Oral N-acetylcysteine for Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
PDE6A Gene Therapy for Retinitis Pigmentosa PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Promising ROd-cone DYstrophy Gene therapY PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) PHASE1/PHASE2RECRUITING
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effects of Lutein in Retinitis Pigmentosa PHASE1/PHASE2COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Prospective Natural History Study of Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Retrospective Natural History Study of Retinitis Pigmentosa nanUNKNOWN
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE6B binder may also engage these)

ProteinNameSimilarity
P23439 — 1.000 P23439 →
P33726 — 1.000 P33726 →
P23440 — 1.000 P23440 →
Q91ZQ1 — 0.998 Q91ZQ1 →
Q28263 — 0.998 Q28263 →
P11541 — 0.997 P11541 →
PDE6A Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 0.997 landscape →
P16586 — 0.997 P16586 →
PDE6C Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' 0.997 landscape →
P52731 — 0.996 P52731 →
P27664 — 0.996 P27664 →
B4LVU6 — 0.993 B4LVU6 →
O54735 — 0.992 O54735 →
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.991 landscape →
Q1KKS3 — 0.991 Q1KKS3 →
B3LVW5 — 0.991 B3LVW5 →
O77746 — 0.990 O77746 →
PDE11A Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A 0.989 landscape →
Q8CG03 — 0.988 Q8CG03 →
B3P3K2 — 0.987 B3P3K2 →
Q8VID6 — 0.987 Q8VID6 →
P0C1Q2 — 0.987 P0C1Q2 →
Q298P4 — 0.986 Q298P4 →
Q28156 — 0.986 Q28156 →
B4HEM4 — 0.985 B4HEM4 →
P91119 — 0.985 P91119 →
B4K9L4 — 0.984 B4K9L4 →
Q9VFI9 — 0.984 Q9VFI9 →
B4NAL6 — 0.983 B4NAL6 →
B4PSS5 — 0.983 B4PSS5 →